Published in Ther Adv Med Oncol on January 01, 2013
Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol (1994) 2.94
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.89
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.13
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res (1998) 1.21
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2012) 0.91
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med (2010) 0.90
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Ther Adv Med Oncol (2013) 0.82
Cancer-related fatigue: a review. Rev Assoc Med Bras (2011) 1.73
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol (2012) 1.39
Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol (2012) 1.36
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol (2009) 1.09
Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med (2011) 1.07
New photodynamic therapy protocol to treat AIDS-related Kaposi's sarcoma. Photomed Laser Surg (2006) 1.03
Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol (2012) 0.99
A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol (2010) 0.95
Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol (2010) 0.93
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol (2012) 0.91
Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Neoplasia (2007) 0.91
Dynamic sentinel node biopsy for inguinal lymph node staging in patients with penile cancer: a systematic review and cumulative analysis of the literature. Ann Surg Oncol (2011) 0.89
Management of advanced prostate cancer. Rev Assoc Med Bras (2008) 0.87
Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer (2010) 0.85
[Analysis of delays in diagnosis and treatment of breast cancer patients at a public hospital]. Rev Assoc Med Bras (2008) 0.85
Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors. Sao Paulo Med J (2009) 0.83
Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat (2004) 0.82
The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials. Contemp Clin Trials (2012) 0.81
Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials. Clin Genitourin Cancer (2011) 0.81
Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue. BJU Int (2013) 0.81
Quality of internet information available to patients on websites in Portuguese. Rev Assoc Med Bras (2012) 0.81
Increased serum CA-125 levels in patients with lung cancer post thoracotomy. South Med J (2009) 0.80
[Incidence of the burnout syndrome among Brazilian cancer physicians]. Rev Assoc Med Bras (2006) 0.80
Interventional procedures for cancer pain management. Einstein (Sao Paulo) (2013) 0.80
Multivitamins do not improve radiation therapy-related fatigue: results of a double-blind randomized crossover trial. Am J Clin Oncol (2007) 0.79
[Evaluation of non-oncologist physician's knowledge and attitude towards cancer screening and preventive actions]. Rev Assoc Med Bras (2004) 0.79
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer (2011) 0.78
Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu). Tumori (2011) 0.78
Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am J Hematol (2002) 0.78
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. Anticancer Drugs (2015) 0.77
Experience with the ABC Foundation School of Medicine undergraduate meeting. Rev Assoc Med Bras (2010) 0.77
Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine. J Pharm Pharmacol (2010) 0.77
Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer. Lung Cancer (2007) 0.77
Heparan sulfate mediates trastuzumab effect in breast cancer cells. BMC Cancer (2013) 0.77
Formal statistical testing and inference in randomized phase II trials in medical oncology. Am J Clin Oncol (2013) 0.76
Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer (2014) 0.75
[The training the physician and the communication of a patient's death to family members]. Rev Assoc Med Bras (2005) 0.75
Treatment of breast cancer patients from a public healthcare system in a private center: costs of care for a pilot public-private partnership in oncology. Einstein (Sao Paulo) (2013) 0.75
Treatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care plan. Case Rep Oncol (2013) 0.75
Paullinia cupana for control of hot flashes in breast cancer patients: a pilot study. Einstein (Sao Paulo) (2013) 0.75
Uncaria tomentosa (cat's claw) improves quality of life in patients with advanced solid tumors. J Altern Complement Med (2014) 0.75
[How to consent without understanding?]. Rev Assoc Med Bras (2009) 0.75
Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial. Acta Haematol (2006) 0.75
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas. Sao Paulo Med J (2008) 0.75
[Metastatic melanoma of the gallbladder mimicking Bladder Calculi]. Rev Assoc Med Bras (2005) 0.75
Does Time-to-Chemotherapy Impact the Outcomes of Resected Ovarian Cancer? Meta-analysis of Randomized and Observational Data. Int J Gynecol Cancer (2017) 0.75
[Absolute number or lymphonodal quotient: which is the best prognostic factor for women with breast neoplasms? ]. Rev Assoc Med Bras (2006) 0.75
[Clinical research conducted by medical students: its potential for learning and the national scientific production]. Rev Assoc Med Bras (2006) 0.75
[A new paradigm for the treatment of cancer]. Rev Assoc Med Bras (2004) 0.75
A medical student-staffed outpatient oncology clinic: a 10-year Brazilian experience. J Cancer Educ (2008) 0.75
[Prospective evaluation of clinical and Doppler ultrasound characteristics of cancer patients with suspicion of deep venous thrombosis]. Rev Assoc Med Bras (2006) 0.75
Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial. J Pain Symptom Manage (2012) 0.75
[Professional or household performance of patients with breast cancer undergoing chemotherapy]. Rev Assoc Med Bras (2009) 0.75
Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial. Acta Haematol (2004) 0.75